GlassScriptPhysician profile
Urszula Polska
NPI 1669882619
$3,282.32
in general payments reported to CMS, 2019-2025
24 companies · $608 in 2025
The $608 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $399 · 2022: $332 · 2023: $1,088 · 2024: $857 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $412.48 | 2021-2025 | Lokelma, Airsupra |
| Novo Nordisk INC | $385.42 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $360.63 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Actelion Pharmaceuticals US, INC. | $245.29 | 2024-2025 | Opsumit, Uptravi |
| Amgen INC. | $178.45 | 2024-2025 | Repatha |
| Axsome Therapeutics, INC. | $135.47 | 2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $134.99 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $130.52 | 2024-2025 | |
| Daiichi Sankyo INC. | $125.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $122.11 | 2023 | Givlaari |
| Alexion Pharmaceuticals, INC. | $121.35 | 2024 | |
| Abbvie INC. | $119.04 | 2023 | |
| Boston Scientific Corporation | $112.06 | 2023 | Watchman Access System |
| Medtronic, INC. | $106.19 | 2023-2024 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $102.63 | 2023 | Spravato |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $94.90 | 2025 | Zoryve |
| Abbott Laboratories | $71.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.00 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $63.60 | 2021 | |
| Organogenesis INC. | $58.44 | 2022 | |
| Stryker Corporation | $49.76 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $44.56 | 2024 | |
| Dexcom, INC. | $24.46 | 2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $13.92 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Urszula Polska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.